Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

November 10, 2017: By Jon Swedien

alimera-sciencesAlimera Sciences posted Q3-2017 net revenues of $9.8 million, an 18 percent increase compared with Q3-2016, the company reported Nov. 1.

The Alpharetta, Georgia-based company markets Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg for the treatment of diabetic macular edema (DME).

Iluvien is the first DME treatment to deliver 36 months of continuous, low-dose corticosteroid with a single injection, Alimera said. It received US approval in September 2014 and is also available in 17 other countries.

Alimera CEO Dan Myers told investors in a conference call Nov. 2 that the company’s sales force was using study data to urge doctors to use Iluvien more frequently.

Typically, doctors have used Iluvien with patients who have not responded well to anti-VEGFs, Myers said. The study data, however, showed that Iluvien could lessen treatment burden for patients whose DME is well controlled by anti-VEGFs, Myers said.

The data he referred to showed that treatment with Iluvien lessened some patients’ need for anti-VEGF injections from once every 2.9 months to once every 22 months, Alimera said.

The study was conducted at four practices, involved more than 20 physicians, and included 130 patients (160 eyes), Myers said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Imprimis’ Q3-2017 Ophthalmic Revenues Increase 60 Percent, Total $4.9 Million

iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

Bill Link, PhD, Joins LENSAR as Board Chairman

Apellis Prices $150 Million Initial Public Offering

Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

Tivanisiran is Generic Name for Sylentis’ Dry Eye Candidate

Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

Iridex’ Revenues Increase 11 Percent in Q3-2017; 111 Cyclo G6 Systems, 7,800 G6 Probes Shipped

Glaukos’ Net Sales Increase 37 Percent in Q3-2017

Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

Opternative Sues Warby Parker Over Online Eye Exams

Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022